Synonyms: GS 4875 | GS-4875
Compound class:
Synthetic organic
Comment: Tilpisertib (GS-4875) is an inhibitor of the serine/ threonine kinase Cot (a.k.a. MAP3K8/TPL2). It was developed by Gilead Sciences as a potential anti-inflammatory drug to treat auto-inflammatory diseases. The chemical structure is amongst those that are claimed as Cot (a.k.a. MAP3K8/TPL2) modulators in patent WO2020252151A1 [1]. Inhibition of Cot (which is an upstream regulator in the MEK-ERK pathway) is expected to reduce production and signalling of TNFα. Gilead's development pipeline now contains a TPL2 inhibitor, GS-5290, that is in phase 1 for inflammatory bowel disease. GS-5290 may be follow-up lead compound tilpisertib fosmecarbil.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
6-[[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]amino]-8-chloro-4-(2,2-dimethylpropylamino)quinoline-3-carbonitrile |
International Nonproprietary Names | |
INN number | INN |
11442 | tilpisertib |
Synonyms |
GS 4875 | GS-4875 |
Database Links | |
CAS Registry No. | 2065153-41-3 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4802154 |
GtoPdb PubChem SID | 472319216 |
PubChem CID | 124181541 |
Search Google for chemical match using the InChIKey | VFGSKBLZRDRHOI-ZAGPDIDGSA-N |
Search Google for chemicals with the same backbone | VFGSKBLZRDRHOI |
Search PubMed clinical trials | tilpisertib |
Search PubMed titles | tilpisertib |
Search PubMed titles/abstracts | tilpisertib |
UniChem Compound Search for chemical match using the InChIKey | VFGSKBLZRDRHOI-ZAGPDIDGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VFGSKBLZRDRHOI-ZAGPDIDGSA-N |